CLAIMS

What is claimed is:

- 1. A method for treating or preventing a tumor necrosis factor-mediated disease in an individual in need thereof comprising co-administering a tumor necrosis factor antagonist and a CD4+ T cell inhibiting agent to the individual, in therapeutically effective amounts.
- 2. A method of Claim 1 wherein the tumor necrosis factor antagonist and a CD4+ T cell inhibiting agent are administered simultaneously.
- 3. A method of Claim 1 wherein the tumor necrosis factor antagonist and a CD4+ T cell inhibiting agent are administered sequentially.
 - 4. A method of Claim 1 wherein the tumor necrosis factor-mediated disease is selected from the group consisting of: autoimmune disease, acute or chronic immune disease, inflammatory disease and neurodegenerative disease.
- 5. A method of Claim 4 wherein the CD4+ T cell inhibiting agent is cyclosporin or analog thereof.
 - 6. A method of Claim 5 wherein the tumor necrosis factor antagonist is an antitumor necrosis factor antibody or fragment thereof.
 - 7. A method of Claim 6 wherein the antibody is a chimeric antibody.
- 8. A method of Claim 5 wherein the tumor necrosis factor antagonist is a receptor molecule which binds to tumor necrosis factor.
 - 9. A method of Claim 8 wherein the receptor molecule is a tumor necrosis factor receptor/immunoglobulin G fusion protein.

5

15

- 10. A method of Claim 5 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis release or its action on target cells.
- 11. A method of Claim 10 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor.
 - 12. A method of Claim 11 wherein the phosphodiesterase inhibitor is pentoxifylline.
 - 13. A method of Claim 10 wherein the tumor necrosis factor antagonist is thalidomide.
- 14. A method of Claim 1 wherein an anti-inflammatory agent is administered in conjunction with the CD4+ T cell inhibiting agent and the tumor necrosis factor antagonist.
 - A method for treating or preventing rheumatoid arthritis in an individual in need thereof comprising administering to the individual cyclosporin or analog thereof in combination with a tumor necrosis factor antagonist, in therapeutically effective amounts.
 - 16. A method of Claim 15 wherein the tumor necrosis factor antagonist is an antitumor necrosis factor antibody or fragment thereof.
 - 17. A method of Claim 16 wherein the antibody is a chimeric antibody.
- 18. A method of Claim 15 wherein the tumor necrosis factor antagonist is a receptor molecule which binds to tumor necrosis factor.
 - 19. A method of Claim 18 wherein the receptor molecule is a tumor necrosis factor receptor/immunoglobulin G fusion protein.

10

- 20. A method of Claim 15 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis factor release or its action on target cells.
- A method of Claim 20 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor.
 - 22. A method of Claim 21 wherein the phosphodiesterase inhibitor is pentoxifylline.
 - A method for treating or preventing Crohn's disease in an individual in need thereof comprising administering to the individual cyclosporin or analog thereof in combination with a tumor necrosis factor antagonist, in therapeutically effective amounts.
 - A method of Claim 23 wherein the tumor necrosis factor antagonist is an antitumor necrosis factor antibody or fragment thereof.
 - 25. A method of Claim 24 wherein the antibody is a chimeric antibody.
- A method of Claim 23 wherein the tumor necrosis factor antagonist is a receptor molecule which binds to tumor necrosis factor.
 - 27. A method of Claim 26 wherein the receptor molecule is a tumor necrosis factor receptor/immunoglobulin G fusion protein.
- A method of Claim 23 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis factor release or its action on target cells.
 - 29. A method of Claim 28 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor.
 - 30. A method of Claim 29 wherein the phosphodiesterase inhibitor is pentoxifylline.

- A method for treating or preventing acute or chronic immune disease associated with a transplantation in an individual comprising administering to the individual cyclosporin or analog thereof in combination with a tumor necrosis factor antagonist, in therapeutically effective amounts.
- A method of Claim 31 wherein the transplantation is selected from the group consisting of: renal transplantation, cardiac transplantation, bone marrow transplantation, liver transplantation, pancreatic transplantation, small intestine transplantation, skin transplantation and lung transplantation.
- A method of Claim 31 wherein the tumor necrosis factor antagonist is an antitumor necrosis factor antibody or fragment thereof.
 - 34. A method of Claim 33 wherein the antibody is a chimeric antibody.
 - 35. A method of Claim 31 wherein the tumor necrosis factor antagonist is a receptor molecule which binds to tumor necrosis factor.
- A method of Claim 35 wherein the receptor molecule is a tumor necrosis factor/immunoglobulin G fusion protein.
 - 37. A method of Claim 33 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis factor release or its action on target cells.
- A method of Claim 37 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor.
 - 39. A method of Claim 38 wherein the phosphodiesterase inhibitor is pentoxifylline.
 - 40. A composition comprising a tumor necrosis factor antagonist and a CD4+ T cell inhibiting agent.

10

- 41. A composition of Claim 40 wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or fragment thereof.
- 42. A composition of Claim 41 wherein the antibody is a chimeric antibody and the CD4+ T cell inhibiting agent is cyclosporin or an analog thereof.
- A composition of Claim 40 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis factor release or its action on target cells.
 - A composition of Claim 43 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor and the CD4+ T cell inhibiting agent is cyclosporin or an analog thereof.
 - 45. A composition of Claim 44 wherein the phosphodiesterase inhibitor is pentoxifylline.